Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.

Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP.

Oncotarget. 2016 Sep 1. doi: 10.18632/oncotarget.11785. [Epub ahead of print]

2.

VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL 2nd, Oelke M, Schneck JP, Webb TJ.

Clin Cancer Res. 2016 Aug 15;22(16):4249-58. doi: 10.1158/1078-0432.CCR-15-2518. Epub 2016 Apr 13.

PMID:
27076627
3.

Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Perica K, Bieler JG, Schütz C, Varela JC, Douglass J, Skora A, Chiu YL, Oelke M, Kinzler K, Zhou S, Vogelstein B, Schneck JP.

ACS Nano. 2015 Jul 28;9(7):6861-71. doi: 10.1021/acsnano.5b02829. Epub 2015 Jul 14.

PMID:
26171764
4.

Telomere Length as an Indicator of the Robustness of B- and T-Cell Response to Influenza in Older Adults.

Najarro K, Nguyen H, Chen G, Xu M, Alcorta S, Yao X, Zukley L, Metter EJ, Truong T, Lin Y, Li H, Oelke M, Xu X, Ling SM, Longo DL, Schneck J, Leng S, Ferrucci L, Weng NP.

J Infect Dis. 2015 Oct 15;212(8):1261-9. doi: 10.1093/infdis/jiv202. Epub 2015 Mar 31.

PMID:
25828247
5.

Adoptive T cell immunotherapy for cancer.

Perica K, Varela JC, Oelke M, Schneck J.

Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004. doi: 10.5041/RMMJ.10179. eCollection 2015 Jan. Review.

6.

CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.

Bruns H, Bessell C, Varela JC, Haupt C, Fang J, Pasemann S, Mackensen A, Oelke M, Schneck JP, Schütz C.

Clin Cancer Res. 2015 May 1;21(9):2075-83. doi: 10.1158/1078-0432.CCR-14-2696. Epub 2015 Jan 15.

7.

MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth.

Schütz C, Zoso A, Peng S, Bennett JD, Schneck JP, Oelke M.

Immun Inflamm Dis. 2014 Nov;2(3):181-92. doi: 10.1002/iid3.35. Epub 2014 Nov 11.

8.

Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells.

Schütz C, Fleck M, Schneck JP, Oelke M.

J Vis Exp. 2014 Aug 11;(90):e51859. doi: 10.3791/51859.

9.

Sprouty-2 regulates HIV-specific T cell polyfunctionality.

Chiu YL, Shan L, Huang H, Haupt C, Bessell C, Canaday DH, Zhang H, Ho YC, Powell JD, Oelke M, Margolick JB, Blankson JN, Griffin DE, Schneck JP.

J Clin Invest. 2014 Jan;124(1):198-208.

10.

Nanoscale artificial antigen presenting cells for T cell immunotherapy.

Perica K, De León Medero A, Durai M, Chiu YL, Bieler JG, Sibener L, Niemöller M, Assenmacher M, Richter A, Edidin M, Oelke M, Schneck J.

Nanomedicine. 2014 Jan;10(1):119-29. doi: 10.1016/j.nano.2013.06.015. Epub 2013 Jul 24.

11.

T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs.

de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, Marques ET.

PLoS Negl Trop Dis. 2013;7(1):e1938. doi: 10.1371/journal.pntd.0001938. Epub 2013 Jan 31.

12.

Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.

Webb TJ, Li X, Giuntoli RL 2nd, Lopez PH, Heuser C, Schnaar RL, Tsuji M, Kurts C, Oelke M, Schneck JP.

Cancer Res. 2012 Aug 1;72(15):3744-52. doi: 10.1158/0008-5472.CAN-11-2695. Epub 2012 May 30.

13.

IL-2 upregulates CD86 expression on human CD4(+) and CD8(+) T cells.

Paine A, Kirchner H, Immenschuh S, Oelke M, Blasczyk R, Eiz-Vesper B.

J Immunol. 2012 Feb 15;188(4):1620-9. doi: 10.4049/jimmunol.1100181. Epub 2012 Jan 13.

14.

Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies.

Tischer S, Basila M, Maecker-Kolhoff B, Immenschuh S, Oelke M, Blasczyk R, Eiz-Vesper B.

J Transl Med. 2011 Oct 12;9:175. doi: 10.1186/1479-5876-9-175.

15.

Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors.

Lee JB, Oelke M, Ramachandra L, Canaday DH, Schneck JP.

Immun Ageing. 2011 Aug 16;8:6. doi: 10.1186/1742-4933-8-6.

16.

HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.

Chiu YL, Schneck JP, Oelke M.

J Vis Exp. 2011 Apr 11;(50). pii: 2801. doi: 10.3791/2801.

17.

Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.

Schütz C, Oelke M, Schneck JP, Mackensen A, Fleck M.

Immunotherapy. 2010 Jul;2(4):539-50. doi: 10.2217/imt.10.26. Review.

18.

Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease.

Hua J, Ma X, Webb T, Potter JJ, Oelke M, Li Z.

J Lipid Res. 2010 Jul;51(7):1696-703. doi: 10.1194/jlr.M003004. Epub 2010 Feb 24.

19.

Dynamic regulation of functionally distinct virus-specific T cells.

Ndhlovu ZM, Oelke M, Schneck JP, Griffin DE.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3669-74. doi: 10.1073/pnas.0915168107. Epub 2010 Feb 4.

20.

Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.

Oelke M, Schneck JP.

Immunol Res. 2010 Jul;47(1-3):248-56. doi: 10.1007/s12026-009-8156-z. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk